Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...
SHA: 688488
Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has...
Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...
Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...
Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...
Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...
Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...
Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...
Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...
Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...
Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...
Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...
Aidea Pharmaceutical Acquires 19.96% ND Pharm Stake to Boost Urokinase Business
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND...